Serum Cytokeratin 19 Fragment Antigen 21-1 as a Diagnostic and Prognostic Biomarker for Thymic Carcinoma in Thymic Masses
European Journal of Cardio-Thoracic Surgery · 2026
DOI: 10.1093/ejcts/ezag017 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2026. Verfasst von Ziyun Shen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China. Hauptthemen laut MEDLINE: Thymus Neoplasms, Keratin-19, Thymoma, Biomarkers, Tumor. Die Arbeit nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
The accurate differentiation of thymic masses, particularly thymic carcinoma (TC), is imperative for guiding optimal treatment selection. This study investigated potential non-invasive biomarkers for discerning thymic malignancies and evaluated their clinical applicability.
Methods
Clinicopathological data from 1897 patients who underwent surgical resection for thymic masses across 2 institutions were retrospectively analysed. Associations between serum tumour markers and TC diagnosis were assessed using the area under the receiver operating characteristic curve (AUC). The clinical utility of the identified tumour markers was further evaluated.
Results
In the discovery cohort from Shanghai Pulmonary Hospital (SPH), cytokeratin 19 fragment antigen 21-1 (CYFRA 21-1) levels were significantly higher in the TC group compared to both the thymoma group and the non-thymic epithelial tumour (non-TET) group (median of 2.38 ng/mL vs 1.39 ng/mL or 1.28 ng/mL, both P < .001), with AUC value of 0.778 (95% CI: 0.735-0.822) compared to thymoma and 0.808 (95% CI: 0.766-0.849) compared to non-TET group. Validation in the cohort from Renmin Hospital of Wuhan University further demonstrated significant discrimination of CYFRA 21-1 for TC diagnosis (vs thymoma: AUC = 0.681 [95% CI: 0.518-0.843]; vs non-TET: AUC = 0.801 [95% CI: 0.622-0.980]). Furthermore, high CYFRA 21-1 levels were also correlated with a shorter median disease-free survival compared to the low CYFRA 21-1 group (10.0 years vs 14.9 years, P < .001) in patients with TET in the SPH cohort.
Conclusions
CYFRA 21-1 emerges as a reliable diagnostic biomarker for distinguishing TC from other thymic masses. Moreover, it holds promise for prognosis evaluation and potentially for recurrence surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
- Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
ORCID-Profile: Peng Zhang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Shen, Z., Liu, Y., Zhu, T., Zhu, X., Zheng, Y., Qiu, J., Teng, M., Fan, P., Ji, S., & Zhang, P. (2026). Serum Cytokeratin 19 Fragment Antigen 21-1 as a Diagnostic and Prognostic Biomarker for Thymic Carcinoma in Thymic Masses. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezag017
Vancouver
Shen Z, Liu Y, Zhu T, Zhu X, Zheng Y, Qiu J, et al. Serum Cytokeratin 19 Fragment Antigen 21-1 as a Diagnostic and Prognostic Biomarker for Thymic Carcinoma in Thymic Masses. European Journal of Cardio-Thoracic Surgery. 2026. doi:10.1093/ejcts/ezag017
BibTeX
@article{Shen2026,
author = {Shen, Ziyun and Liu, Yue and Zhu, Tieyuan and Zhu, Xinsheng and Zheng, Yingzhi and Qiu, Jianing and Teng, Meixin and Fan, Pengyu and Ji, Shuyu and Zhang, Peng},
title = {Serum Cytokeratin 19 Fragment Antigen 21-1 as a Diagnostic and Prognostic Biomarker for Thymic Carcinoma in Thymic Masses},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2026},
doi = {10.1093/ejcts/ezag017}
}
EUVIMED